Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. Company
    COX   FR0013018124

NICOX SA.

(COX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Nicox SA.
Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

Number of employees : 34 people.
Sales per Business
20192020Delta
Ophthalmic Product8.26100%14.42100% +74.61%
EUR in Million
Sales per region
20192020Delta
Global8.26100%14.42100% +74.61%
EUR in Million
Managers
Name Title Age Since
Michele Garufi Chairman & Chief Executive Officer 67 2010
Sandrine Gestin Vice President-Finance 53 2015
José Boyer Head-Research & Development - -
Doug Hubatsch Chief Scientific Officer - 2021
Jean-François Labbé Independent Director 70 2010
Adrienne L. Graves, Dr. Independent Director 66 2014
Luzi Andreas von Bidder Independent Director 68 2014
Lester J. Kaplan, Dr. Independent Director 70 2014
Lauren P. Silvernail Independent Director 62 2017
Gavin M. Spencer, Dr. Chief Business Officer & Executive Vice President 50 -
Members of the board
Name Title Age Since
Michele Garufi Chairman & Chief Executive Officer 67 2010
Jean-François Labbé Independent Director 70 2010
Adrienne L. Graves, Dr. Independent Director 66 2014
Luzi Andreas von Bidder Independent Director 68 2014
Lester J. Kaplan, Dr. Independent Director 70 2014
Lauren P. Silvernail Independent Director 62 2017
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 37,111,985 33,063,756 89.1% 0 0.0% 89.1%
Shareholders
NameEquities%
Armistice Capital LLC 5,920,000 13.7%
HBM Partners AG 3,359,102 7.79%
HBM Partners AG (Investment Management) 2,619,102 6.07%
OrbiMed Advisors Private Equity 1,309,165 3.03%
Michele Garufi 577,051 1.34%
Medical Strategy GmbH 461,036 1.07%
Apo Asset Management GmbH 401,006 0.93%
Banque Publique d'Investissement 384,300 0.89%
Dimensional Fund Advisors LP 252,349 0.58%
Nicox S.A. 223,406 0.52%
Holdings
NameEquities%Valuation
NICOX SA. (COX) 223,406 0.52% 649,117 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Compartiment B
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME
Stock Exchange Codes
- Bloomberg Code :  COX:FP
- Reuters Code :  NCOX.PA
- Datastream Code :  F:NICX
Company contact information
Nicox SA.
Drakkar 2 - Bâtiment D 2405 Route des Dolines
BP 313
FR-06560 Valbonne

Phone : +33 (0)4 97 24 53 00
Fax : +33 (0)4 97 24 53 99
web site : http://www.nicox.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Nicox SA.